Prenetics Global Limited (PRE) Raises 2026 Guidance to $220M-$230M

Prenetics Global Limited (PRE) increased its 2026 revenue guidance to $220M-$230M and initiated 2027 IM8 revenue guidance of $400M or more. The 2027 forecast excludes potential revenue from upcoming product launches. No prior guidance was provided for comparison.

Original reporting
Published Nov 16, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prenetics Global Limited (PRE) Raises 2026 Guidance to $220M-$230M — source image
Decision brief

The 30-second read

$PREBullishMed
01

Why it matters

The upgraded revenue guidance signals stronger growth momentum, which could attract growth‑oriented investors.

02

Market read

Guidance lift is the primary catalyst for PRE's near‑term price action.

03

What to watch

Potential execution risk for upcoming product launches not reflected in the guidance.

Relevance 6/10Novelty 6/10Timing: post-market today

Background

Prenetics Global Ltd (NASDAQ:PRE) is a consumer health and diagnostics company that previously reported Q3 2026 results on Aug 26, 2026.

Company-level read

Ticker impact

$PREBullishHigh confidence
Context

Prenetics raised its full-year 2026 revenue guidance to $220M-$230M and set 2027 IM8 revenue guidance of $400M+.

Expected impact

potential upside as investors price in higher revenue expectations

Evidence & confidence

The new guidance is fresh information not previously disclosed and materially raises revenue expectations.

Market effects

Higher guidance may lift sentiment in the consumer health and diagnostics sector.

Positive for Asian biotech/healthcare equities where Prenetics has exposure.

Limited to investors tracking growth-stage health tech stocks.

Counterpoint

If the guidance is overly optimistic, future earnings could miss expectations, leading to a sell‑off.

Key entities

  • Prenetics Global Limited

    Consumer health and diagnostics firm issuing new revenue guidance.

Related articles

$PREMedAI 8/10

Prenetics Global reports Q3 results

Prenetics Global reported a Q3 net loss of $25.4M but revenue grew 171.6% year-over-year to $64.1M, exceeding estimates by $0.89M. The company's cash and current financial assets increased to $111.5M by September 30, 2026, up from $109.4M three months earlier.

$PREMed

Prenetics Global Ltd (PRE): Financial results for FY2027

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven

$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.